Can slow roll inflation induce relevant helical magnetic fields?

We study the generation of helical magnetic fields during single field inflation induced by an axial coupling of the electromagnetic field to the inflaton. During slow roll inflation, we find that such a coupling always leads to a blue spectrum with $B^2(k) \propto k$, as long as the theory is treated perturbatively. The magnetic energy density at the end of inflation is found to be typically too small to backreact on the background dynamics of the inflaton. We also show that a short deviation from slow roll does not result in strong modifications to the shape of the spectrum. We calculate the evolution of the correlation length and the field amplitude during the inverse cascade and viscous damping of the helical magnetic field in the radiation era after inflation. We conclude that except for low scale inflation with very strong coupling, the magnetic fields generated by such an axial coupling in single field slow roll inflation with perturbative coupling to the inflaton are too weak to provide the seeds for the observed fields in galaxies and clusters.Comment: 33 pages 6 figures; v4 to match the accepted version to appear in JCA

Polarization independent hot electron production from modulated solid surfaces

We present measurements of hard x-rays in the 50-300 keV range from copper plasmas produced by 100 fs, 806 nm laser pulses at a peak intensity ~ 1016 W cm-2. Surface roughness, even at the tens of nanometer level, is shown to influence the emission characteristics. The enhanced emission from rough targets is attributed to depolarization of light as well as extra absorption facilitated by the surface irregularities.Comment: 19 pages, 4 figures. submitted to Opt.Commu

Resonant magnetic fields from inflation

We propose a novel scenario to generate primordial magnetic fields during inflation induced by an oscillating coupling of the electromagnetic field to the inflaton. This resonant mechanism has two key advantages over previous proposals. First of all, it generates a narrow band of magnetic fields at any required wavelength, thereby allaying the usual problem of a strongly blue spectrum and its associated backreaction. Secondly, it avoids the need for a strong coupling as the coupling is oscillating rather than growing or decaying exponentially. Despite these major advantages, we find that the backreaction is still far too large during inflation if the generated magnetic fields are required to have a strength of order 10^{-15} Gauss today on observationally interesting scales. We provide a more general no-go argument, proving that this problem will apply to any model in which the magnetic fields are generated on subhorizon scales and freeze after horizon crossing.Comment: 13 pages + 7 pages of appendices and references, 3 figures, matches published versio

DNA DSB Repair Dynamics following Irradiation with Laser-Driven Protons at Ultra-High Dose Rates

Protontherapy has emerged as more effective in the treatment of certain tumors than photon based therapies. However, significant capital and operational costs make protontherapy less accessible. This has stimulated interest in alternative proton delivery approaches, and in this context the use of laser-based technologies for the generation of ultra-high dose rate ion beams has been proposed as a prospective route. A better understanding of the radiobiological effects at ultra-high dose-rates is important for any future clinical adoption of this technology. In this study, we irradiated human skin fibroblasts-AG01522B cells with laser-accelerated protons at a dose rate of 10 9 Gy/s, generated using the Gemini laser system at the Rutherford Appleton Laboratory, UK. We studied DNA double strand break (DSB) repair kinetics using the p53 binding protein-1(53BP1) foci formation assay and observed a close similarity in the 53BP1 foci repair kinetics in the cells irradiated with 225 kVp X-rays and ultra- high dose rate protons for the initial time points. At the microdosimetric scale, foci per cell per track values showed a good correlation between the laser and cyclotron-accelerated protons indicating similarity in the DNA DSB induction and repair, independent of the time duration over which the dose was delivered

Application of compact laser-driven accelerator X-ray sources for industrial imaging

X-rays generated by betatron oscillations of electrons in a laser-driven plasma accelerator were characterised and applied to imaging industrial samples. With a 125TW laser, a low divergence beam with 5.2±1.7 × 107photonsmrad−2 per pulse was produced with a synchrotron spectrum with a critical energy of 14.6±1.3keV. Radiographs were obtained of a metrology test sample, battery electrodes, and a damage site in a composite material. These results demonstrate the suitability of the source for non-destructive evaluation applications. The potential for industrial implementation of plasma accelerators is discussed

Laser Wakefield accelerator modelling with variational neural networks

A machine learning model was created to predict the electron spectrum generated by a GeVclass laser wakefield accelerator. The model was constructed from variational convolutional neural networks which mapped the results of secondary laser and plasma diagnostics to the generated electron spectrum. An ensemble of trained networks was used to predict the electron spectrum and to provide an estimation of the uncertainty on that prediction. It is anticipated that this approach will be useful for inferring the electron spectrum prior undergoing any process which can alter or destroy the beam. In addition, the model provides insight into the scaling of electron beam properties due to stochastic fluctuations in the laser energy and plasma electron density

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings: The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2·7 times longer with liraglutide than with placebo (95% CI 1·9 to 3·9, p<0·0001), corresponding with a hazard ratio of 0·21 (95% CI 0·13–0·34). Liraglutide induced greater weight loss than placebo at week 160 (–6·1 [SD 7·3] vs −1·9% [6·3]; estimated treatment difference −4·3%, 95% CI −4·9 to −3·7, p<0·0001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation: In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding: Novo Nordisk, Denmark

Cold avalanche ionisation

Peer reviewed: YesNRC publication: Ye

Measuring attosecond ionization dynamics inside dielectrics

We resolve attosecond dynamics of multiphoton ionization in solids. We subdivide the laser cycle using differential absorption between the major and the minor axes of elliptically polarized beam. \ua92007 Optical Society of America.Peer reviewed: YesNRC publication: Ye